Contact Us

CleanCap® EGFP mRNA - (L-7601)

CleanCap® Enhanced Green Fluorescent Protein mRNA
In stock
Product SKU Unit Size Price Qty
L-7601-100 100 µg
L-7601-1000 1 mg
L-7601-5 5 x 1 mg



The EGFP mRNA expresses an enhanced version of the green fluorescent protein, originally isolated from the jellyfish, Aequorea victoria. EGFP is a commonly used direct detection reporter in mammalian cell culture, yielding bright green fluorescence with an emission peak at 509 nm.

This mRNA is capped using CleanCap® Reagent AG, TriLink's patented co-transciptional capping technology, which results in the naturally occurring Cap-1 structure with >95% capping efficiency. It is manufactured using TriLink’s CleanScript™ method*, polyadenylated, and optimized for mammalian systems. It mimics a fully processed mature mRNA.

CleanCap® Reagent AG produces a base-modified Cap-1 mRNA, which shows superior in vivo activity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA).

CleanScript™ method is TriLink’s proprietary in vitro transcription process that is optimized to minimize dsRNA formation and increase mRNA activity in vivo.

*Starting April 30th, 2024

Sold for research use only under license from Life Technologies.

Product details
Catalog No L-7601
Purity Passes Agarose Gel Mobility
Length 997 nucleotides
Base Composition Unmodified bases
Concentration 1.0 mg/mL
Buffer 1 mM Sodium Citrate pH 6.4
Conversion Factor 40 µg/OD260
Recommended Storage At or below -40°C
Application Reporter Genes
Other Name(s) CleanCap® Enhanced Green Fluorescent Protein mRNA
Technical documents

Safety Data Sheet Look-up

L-7601 Product Insert

CleanCap EGFP ORF Sequence

Products faqs

They all contain an optimal 5′ Cap 1 found in higher eukaryotes for their functionality and stability. They also contain a synthetic 5′ UTR with a strong Kozak sequence for efficient translation and a 3′ UTR derived from mouse alpha-globin. Their key differences lie in the type of CleanCap® analog used and the sequence compositions, which may affect their protein expression and immunogenicity.


CleanCap® mRNAs

CleanCap® mRNAs (5moU)

CleanCap® M6 mRNAs (N1MePsU)

Expression system




5′ cap

Cap 1

Cap 1

Cap 1

Cap analog

CleanCap® AG

CleanCap® AG

CleanCap® M6

5′ and 3′ UTRs




Poly(A) tail

120 nt

120 nt

120 nt

Sequence composition

Unmodified uridines

Uridines substituted with 5-methoxyuridines

Uridines substituted with N1-methylpseudouridines

Protein expression









It is TriLink’s proprietary in vitro transcription method that produces high-quality, high-yield mRNAs from a broad range of sequences. It has been optimized to minimize dsRNA and improve in vivo protein expression from the resulting mRNAs. Please see here for more information.

Our catalog mRNAs are intended for research use and manufactured with procedures in place to minimize endotoxin exposure. However, they are manufactured outside of a cleanroom and thus are not released with an endotoxin specification.  If you need mRNA released with an endotoxin specification or a higher grade of material, please contact [email protected].

We recommend storing the mRNAs at -400 C to -800 C. To minimize freeze-thaw cycles, aliquot the sample into single-use quantities on the first usage. If kept under these conditions, our catalog mRNAs have been shown to maintain stability for at least 2 years.

The sequence reported is just the ORF, start codon to stop codon, for our catalog mRNAs. It does not include the proprietary 5′ UTR, 3′ UTR, or the 120-nt poly-A tail. For full mRNA length and the length of the ORF please see the corresponding product insert.

Our catalog mRNAs are purified through DNase treatment to remove DNA templates, diafiltration to remove salts and small molecules, and oligo dT capture to remove impurities and retain species with poly(A) tails. 

We do not carry Cy5-labeled mRNAs as catalog products. You may order them as a custom mRNA by completing this request form.

We use the dot blot test, which is a qualitative test to determine the relative amount of dsRNA present in a sample. Generally, this test is performed to assess dsRNA levels in mRNAs before and after RP-HPLC purification.

We minimize the dsRNA level in our ready-to-use mRNAs by incorporating stringent processes that consist of:

  • In vitro transcription using our proprietary CleanScript™ method or the CleanCap® M6 protocol
  • Multiple post-IVT purification steps

We also assess dsRNA level in the sample by dot blot as part of quality analysis.

We look for a single main band running to approximately the correct length to pass the gel result.  Some factors such as modified NTPs can make a sample run slightly lower than the expected size.  Sometimes, sequence-related factors such as highly repetitive or UTP-rich regions (especially when modified UTP is used) can result in additional bands.  We take account of all these factors to confirm that the mRNA was manufactured appropriately and the band is sequence specific before passing the results.

The fragment analyzer reports the percent of smear with a chromatogram. The smear analysis corresponds to the full-length integrity of an mRNA sample.

We start by cleaving the 5′ end of the mRNAs, then use LCMS to determine the mass of capped and uncapped species by the following formula:

We use 40 as the extinction coefficient for our mRNAs. Assigning a sequence-specific extinction coefficient for mRNA can be problematic due to its dependence on length and sequence composition.  Factors like final buffer and temperature can also impact results.  Thus, it is standard to use 40 for all mRNA species and not to calculate a coefficient for each sequence as you would with an oligonucleotide.

Certificate of analysis

CoA search tool

Intellectual property

CleanCap capping technology For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at Patents and patent pending, see

Mutant GFP mRNA These products are sold with a Limited Use Label License under sublicense with Life Technologies, Inc. Please review Limited License at

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.

TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.

  1. Castanotto, Daniela; Lin, Min; Kowolik, Claudia; Koch, Troels; Hansen, Bo Rode; Oerum, Henrik; Stein, Cy A. . Protein Kinase C-α is a Critical Protein for Antisense Oligonucleotide-mediated Silencing in Mammalian Cells.
  2. Carlsten, Mattias; Levy, Emily; Karambelkar, Amrita; Li, Linhong; Reger, Robert; Berg, Maria; Peshwa, Madhusudan V.; Childs, Richard W. . Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19.
  3. Luo, X.; Li, B.; Zhang, X.; Zhao, W.; Bratasz, A.; Deng, B.; McComb, D. W.; Dong, Y. . Dual-functional lipid-like nanoparticles for delivery of mRNA and MRI contrast agents.
  4. Dharmalingam, Priya; Rachamalla, Hari Krishna R.; Lohchania, Brijesh; Bandlamudi, Bhanuprasad; Thangavel, Saravanabhavan; Murugesan, Mohankumar K.; Banerjee, Rajkumar; Chaudhuri, Arabinda; Voshavar, Chandrashekhar; Marepally, Srujan . Green Transfection: Cationic Lipid Nanocarrier System Derivatized from Vegetable Fat, Palmstearin Enhances Nucleic Acid Transfections.
  5. Kauffman, Kevin J.; Oberli, Matthias A.; Dorkin, J. Robert; Hurtado, Juan E.; Kaczmarek, James C.; Bhadani, Shivani; Wyckoff, Jeff; Langer, Robert; Jaklenec, Ana; Anderson, Daniel G. . Rapid, Single-Cell Analysis and Discovery of Vectored mRNA Transfection In Vivo with a loxP-Flanked tdTomato Reporter Mouse.
  6. Olden, Brynn R.; Cheng, Yilong; Yu, Jonathan L.; Pun, Suzie H. . Cationic polymers for non-viral gene delivery to human T cells.
  7. Wu, CC;Peterson, A;Zinshteyn, B;Regot, S;Green, R; . Ribosome Collisions Trigger General Stress Responses to Regulate Cell Fate
  8. Schmiderer, L;Subramaniam, A; . Efficient and nontoxic biomolecule delivery to primary human hematopoietic stem cells using nanostraws
  9. Ayad, C;Libeau, P;Lacroix-Gimon, C;Ladavi . LipoParticles: Lipid-Coated PLA Nanoparticles Enhanced In Vitro mRNA Transfection Compared to Liposomes
  10. Li, L;Long, J;Sang, Y;Wang, X;Zhou, X;Pan, Y;Cao, Y;Huang, H;Yang, Z;Yang, J;Wang, S; . Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid
  11. Linares-Fern . Combining an optimized mRNA template with a double purification process allows strong expression of in
  12. Ahn, M;Song, J;Hong, B; . Facile Synthesis of N-Doped Graphene Quantum Dots as Novel Transfection Agents for mRNA and pDNA
  13. Zhang, C;Delawary, M;Huang, P;Korchak, JA;Suda, K;Zubair, AC; . IL-10 mRNA Engineered MSCs Demonstrate Enhanced Anti-Inflammation in an Acute GvHD Model
  14. Palacio-Casta . Mimicking the Biology of Engineered Protein and mRNA Nanoparticle Delivery Using a Versatile Microfluidic Platform
  15. Meyer, RA;Patrick Hussmann, G;Peterson, NC;Luis Santos, J;Tuesca, AD; . A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery
  16. Loo, J;Sicher, I;Goff, A;Kim, O;Clary, N;Alexeev, A;Sulchek, T;Zamarayeva, A;Han, S;Calero-Garcia, M; . Microfluidic transfection of mRNA into human primary lymphocytes and hematopoietic stem and progenitor cells using ultra-fast physical deformations
  17. Larson, NR;Hu, G;Wei, Y;Tuesesca, A;Forrest, ML;Middaugh, CR; . pH-Dependent Phase Behavior and Stability of Cationic Lipid-mRNA Nanoparticles
  18. Tanaka, H;Miyama, R;Sakurai, Y;Tamagawa, S;Nakai, Y;Tange, K;Yoshioka, H;Akita, H; . Improvement of mRNA Delivery Efficiency to a T Cell Line by Modulating PEG-Lipid Content and Phospholipid Components of Lipid Nanoparticles
  19. R . Acid-Sensitive Surfactants Enhance the Delivery of Nucleic Acids
  20. Huang, P;Zhang, C;Delawary, M;Korchak, JA;Suda, K;Zubair, AC; . Development and evaluation of IL-6 overexpressing mesenchymal stem cells (MSCs)
  21. Rajagopal, K;Arjunan, P;Marepally, S;Madhuri, V; . Controlled Differentiation of Mesenchymal Stem Cells into Hyaline Cartilage in miR-140-Activated Collagen Hydrogel
  22. Duggal, R;Santara, S;Gordon, M;Kilgallon, A;Hermanson, D;Childs, R;O'Dwyer, M; . Promising Preliminary Activity of Optimized Affinity, CD38 CAR NK Cells Generated Using a Non-Viral Engineering Approach in Gene Edited Cord Blood Derived NK Cells for the Treatment of Multiple Myeloma
  23. Li, J;Men, K;Gao, Y;Wu, J;Lei, S;Yang, Y;Pan, H; . Single Micelle Vectors based on Lipid/Block Copolymer Compositions as mRNA Formulations for Efficient Cancer Immunogene Therapy
  24. Ren, J;Cao, Y;Li, L;Wang, X;Lu, H;Yang, J;Wang, S; . Self-assembled polymeric micelle as a novel mRNA delivery carrier
  25. Joo, B;Hur, J;Kim, GB;Yun, SG;Chung, AJ; . Highly Efficient Transfection of Human Primary T Lymphocytes Using Droplet-Enabled Mechanoporation
Show more